193 related articles for article (PubMed ID: 30716503)
1. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
Shen SC; Shen CC; Pu TW; Cheng WY
World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
[TBL] [Abstract][Full Text] [Related]
4. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
5. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
8. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
9. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
10. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
11. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
12. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
13. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
14. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
15. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
[TBL] [Abstract][Full Text] [Related]
16. A single-center experience of transsphenoidal endoscopic surgery for acromegaly in 73 patients: results and predictive factors for remission.
Unal TC; Aydoseli A; Ozgen U; Dolas I; Sabanci PA; Aras Y; Ozturk M; Ozata MS; Gul N; Kubat Uzum A; Mutlu U; Bilgic B; Saka E; Yarman S; Sencer A
Br J Neurosurg; 2024 Jun; 38(3):648-653. PubMed ID: 34241568
[TBL] [Abstract][Full Text] [Related]
17. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes.
Nishioka H; Fukuhara N; Horiguchi K; Yamada S
J Neurosurg; 2014 Sep; 121(3):505-10. PubMed ID: 25014437
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
[TBL] [Abstract][Full Text] [Related]
19. SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY.
Anthony JR; Alwahab UA; Kanakiya NK; Pontell DM; Veledar E; Oyesiku NM; Ioachimescu AG
Endocr Pract; 2015 Sep; 21(9):1001-9. PubMed ID: 26121434
[TBL] [Abstract][Full Text] [Related]
20. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
